No record found
capitalstake.com. Provided by * Returns not adjusted for payouts
^The historical stock prices have been adjusted to reflect stock splits to ensure comparability over time.
Company Profile
Citi Pharma Limited incorporated as a private limited company in Pakistan under the repealed Companies Ordinance, 1984 on October 08, 2012. The principal activity of the company is manufacturing and sale of pharmaceuticals, medical chemicals and botanical products.
| Rizwan Ahmad | CEO |
| Nadeem Amjad | Chairperson |
| Ghulam Dastgeer | Company Secretary |
F.D Registrar Services (Pvt.) Ltd.
Aslam Malik & Co. Chartered Accountants
June
Equity Profile
Announcements
| Date | Title | Document |
|---|---|---|
| Feb 13, 2026 | Financial Results for the Quarter Ended December 31, 2025 | View |
| Oct 30, 2025 | TRANSMISSION OF QUARTERLY REPORT FOR THE PERIOD ENDED | View PDF |
| Oct 29, 2025 | Financial Results for the Quarter Ended | View PDF |
| Oct 7, 2025 | Transmission of Annual Report for the Year Ended | View PDF |
| Oct 2, 2025 | Financial Results for the year ended | View PDF |
| Date | Title | Document |
|---|---|---|
| Feb 11, 2026 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
| Feb 4, 2026 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
| Jan 30, 2026 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
| Jan 30, 2026 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
| Jan 30, 2026 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Financials
All numbers in thousands (000's) except EPS
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 13,153,521 | 12,409,239 | 12,396,983 | 9,779,880 |
| Profit after Taxation | 892,039 | 833,464 | 657,984 | 635,884 |
| EPS | 3.90 | 3.65 | 2.88 | 2.88 |
| Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|
| Sales | 3,370,247 | 3,341,108 | 3,534,432 | 3,224,645 |
| Profit after Taxation | 203,691 | 220,375 | 256,979 | 201,497 |
| EPS | 0.89 | 0.96 | 1.12 | 0.88 |

Ratios
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Gross Profit Margin (%) | 15.34 | 12.78 | 12.16 | 13.83 |
| Net Profit Margin (%) | 6.78 | 6.72 | 5.31 | 6.50 |
| EPS Growth (%) | 6.85 | 26.74 | (20.88) | |
| PEG | 3.14 | 0.29 | (0.54) |










Feedback
Terms of Use
https://www.psx.com.pk